This initiative encompasses two different migraine studies focused on the pediatric target population. This study will evaluate the effectiveness of a medication already approved for treating adult migraine attacks. For this study, we will enroll adolescents that are experiencing 1-8 migraine attacks in a one-month period. One study is shorter with a 19-week timespan with 4 study appointments, while the second study will last 58 weeks with 13 office visits.
Between 12-17 years of age
Must have 1-8 migraines per month on average.
6210 Brandt Pike, Suite 102
Dayton, Ohio 45424
(937) 912-4369